Previous Close | 25.56 |
Open | 25.74 |
Bid | 25.49 x 200 |
Ask | 25.57 x 100 |
Day's Range | 25.28 - 25.97 |
52 Week Range | 13.72 - 33.34 |
Volume | |
Avg. Volume | 579,059 |
Market Cap | 1.498B |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics Inc (NASDAQ:PTGX), a biopharmaceutical company, has reported an insider sale according to a recent SEC filing.